Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMNDNASDAQ:CWBRNASDAQ:EVOKNASDAQ:EYEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMNDClearmind Medicine$0.95+0.9%$0.99$0.85▼$2.30$4.05M0.91885,140 shs158,982 shsCWBRCohBar$0.41$0.41$0.00▼$1.01$1.19M1.394,364 shsN/AEVOKEvoke Pharma$2.95-14.7%$2.87$1.94▼$12.32$4.40M0.04124,189 shs54,458 shsEYENEyenovia$4.88+55.4%$1.36$0.85▼$124.80$14.07M1720,999 shs38.84 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMNDClearmind Medicine0.00%-1.68%-2.29%-11.74%-11.33%CWBRCohBar0.00%0.00%0.00%0.00%-47.44%EVOKEvoke Pharma0.00%-12.10%-8.67%-23.97%-55.22%EYENEyenovia0.00%+187.06%+345.66%+206.92%-92.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMNDClearmind Medicine0.797 of 5 stars0.04.00.00.02.21.70.0CWBRCohBarN/AN/AN/AN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AN/AN/AN/AEYENEyenovia0.7682 of 5 stars1.05.00.00.00.60.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMNDClearmind Medicine 0.00N/AN/AN/ACWBRCohBar 0.00N/AN/AN/AEVOKEvoke Pharma 0.00N/AN/AN/AEYENEyenovia 2.00Hold$2.00-59.02% DownsideCurrent Analyst Ratings BreakdownLatest CWBR, EVOK, EYEN, and CMND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2025EYENEyenoviaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00(Data available from 6/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMNDClearmind MedicineN/AN/AN/AN/A$0.73 per shareN/ACWBRCohBarN/AN/AN/AN/A$5.27 per shareN/AEVOKEvoke Pharma$11.59M0.38N/AN/A($9.26) per share-0.32EYENEyenovia$67.06K209.79N/AN/A$16.32 per share0.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMNDClearmind Medicine-$5.26M-$1.22N/A∞N/AN/A-129.21%-61.15%6/12/2025 (Estimated)CWBRCohBar-$12.18MN/A0.00∞N/AN/AN/AN/AN/AEVOKEvoke Pharma-$7.79M-$2.87N/A∞N/A-71.32%-308.49%-53.66%8/11/2025 (Estimated)EYENEyenovia-$27.26M-$58.40N/AN/AN/A-114,639.41%-1,108.24%-139.36%8/11/2025 (Estimated)Latest CWBR, EVOK, EYEN, and CMND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025EYENEyenovia-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 million5/12/2025Q1 2025EVOKEvoke Pharma-$0.33-$0.51-$0.18-$0.51$3.32 million$3.08 million3/13/2025Q1 2025CMNDClearmind MedicineN/A-$0.24N/A-$0.24N/AN/A3/13/2025Q4 2024EVOKEvoke Pharma-$0.25-$0.49-$0.24-$0.49$3.08 million$3.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMNDClearmind MedicineN/AN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AEYENEyenoviaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMNDClearmind Medicine0.011.721.72CWBRCohBarN/AN/AN/AEVOKEvoke PharmaN/A1.441.39EYENEyenovia0.580.740.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMNDClearmind Medicine96.05%CWBRCohBar2.47%EVOKEvoke PharmaN/AEYENEyenovia25.84%Insider OwnershipCompanyInsider OwnershipCMNDClearmind MedicineN/ACWBRCohBar6.51%EVOKEvoke Pharma2.29%EYENEyenovia7.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMNDClearmind MedicineN/A4.27 millionN/ANot OptionableCWBRCohBar102.91 millionN/ANot OptionableEVOKEvoke Pharma41.49 million1.40 millionNot OptionableEYENEyenovia402.88 million1.29 millionOptionableCWBR, EVOK, EYEN, and CMND HeadlinesRecent News About These CompaniesEyenovia Advances Merger Talks With Betaliq And Targets FDA Filing For Optejet DeviceMay 22, 2025 | nasdaq.comEyenovia provides update on potential merger and Optejet developmentMay 20, 2025 | msn.comEyenovia Reports Q1 2025 Progress and FinancialsMay 20, 2025 | tipranks.comEyenovia, Inc. Provides Merger Update with Betaliq and Financial Results for Q1 2025May 19, 2025 | quiverquant.comEyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial ResultsMay 19, 2025 | globenewswire.comEyenovia Faces Nasdaq Delisting Over Equity ShortfallMay 4, 2025 | investing.comEyenovia provides development update on Optejet user filled deviceApril 14, 2025 | pharmabiz.comEyenovia provides development update on Optejet UFDApril 11, 2025 | markets.businessinsider.comEyenovia Provides Development Update on Optejet User Filled Device (UFD)April 10, 2025 | globenewswire.comEyenovia enters non-binding LOI to effect reverse merger with BetaliqMarch 21, 2025 | markets.businessinsider.comEyenovia Shares Drop 14% Amid Betaliq Merger TalksMarch 21, 2025 | finance.yahoo.comEyenovia Plans All-Stock Reverse Merger With BetaliqMarch 20, 2025 | marketwatch.comEyenovia falls on plans to seek reverse mergerMarch 20, 2025 | msn.comEyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with BetaliqMarch 20, 2025 | globenewswire.comEyenovia regains compliancce with Nasdaq Stock MarketFebruary 26, 2025 | markets.businessinsider.comEyenovia Shares Surge After Regaining Nasdaq Compliance: What's Going On?February 26, 2025 | benzinga.comEyenovia Regains Compliance with All Nasdaq Continued Listing RequirementsFebruary 26, 2025 | globenewswire.comEyenovia announces debt restructuring, improving cash runwayFebruary 24, 2025 | markets.businessinsider.comEyenovia, Inc. Announces Amendment to Senior Secured Convertible Debt to Enhance Liquidity and Support Optejet® DevelopmentFebruary 24, 2025 | quiverquant.comEyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic AlternativesFebruary 24, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueQuantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationBy Leo Miller | May 27, 2025View Quantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationCWBR, EVOK, EYEN, and CMND Company DescriptionsClearmind Medicine NASDAQ:CMND$0.95 +0.01 (+0.95%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$0.95 +0.00 (+0.13%) As of 06/6/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.CohBar NASDAQ:CWBR$0.41 0.00 (0.00%) As of 01/23/2025CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.Evoke Pharma NASDAQ:EVOK$2.95 -0.51 (-14.74%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$3.21 +0.26 (+8.81%) As of 06/6/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Eyenovia NASDAQ:EYEN$4.88 +1.74 (+55.41%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$4.46 -0.42 (-8.50%) As of 06/6/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later? MongoDB Affirms Outlook and Accelerates Stock Price Reversal Five Below Pops on Strong Earnings, But Rally May Stall Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
